MWNA
STSA

Marshall Wace North America’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Marshall Wace North America’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$79K Sell
16,888
-1,754
-9% -$9.29K ﹤0.01% 1370
2021
Q2 		$131K Buy
+18,642
New +$101K ﹤0.01% 1379
2019
Q4 		– Sell
-33,380
Closed -$501K – 1693
2019
Q3 		$501K Buy
+33,380
New +$518K ﹤0.01% 812

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's STSA Position: Q3 2021 in Review

Marshall Wace North America reduced its Satsuma Pharmaceuticals, Inc. Common Stock (STSA) stake by 9.4% in Q3 2021, selling an estimated $9.29K and leaving 16,888 shares worth $79K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Marshall Wace North America first reported a position in STSA in Q3 2019 and has held it in 3 quarters since. The position peaked at $501K in Q3 2019. 45 funds tracked by Wall St. Rank hold STSA as of Q3 2021.

  • Marshall Wace North America held 16,888 shares of Satsuma Pharmaceuticals, Inc. Common Stock worth $79K as of Q3 2021.
  • Marshall Wace North America sold 1,754 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $9.29K.
  • Satsuma Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1370 holding.
  • Marshall Wace North America first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and has held it in 3 quarters since.
  • Marshall Wace North America's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $501K in Q3 2019.
  • 45 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.